A US district court has ruled that the FDA must reconsider its decision to reject a long-lasting opioid addiction treatment drug from Braeburn, overthrowing a ruling granting exclusivity to
Oxford-based biopharma Beckley Canopy Therapeutics has raised £7.4 million to develop a range of cannabis-based products for the treatment of pain and to help tackle
